KURA · Kura Oncology, Inc. · Stock research

Price reference: last completed daily close $10.86 on 2026-08-14; 52-week high $12.14 (-10.5%); three-month return +17.8%; RSI(14) 58.3.

KURA — Kura Oncology, Inc.

Current Thesis

The frame in the prior note — a de-risked biotech drifting through a two-year catalyst gap after its approval binary fired on 2025-11-13 — needs one amendment: the commercial line re-accelerated. At the 2026-08-12 Q2 print, KOMZIFTI (ziftomenib) net product revenue was $9.1M, up 57% sequentially from Q1's $5.8M, on roughly 115 new patient starts (+35% QoQ) and more than 250 total prescriptions (+59% QoQ), with Kura claiming a majority share of new patient starts in the relapsed/refractory NPM1-mutant AML menin-inhibitor class, up from the ~40% figure carried through the EHA/Q1 update. Wedbush maintained Outperform and raised its target to $38 the next day (2026-08-13). What has not changed is the structure of the opportunity: the Street's $24–38 targets are underwritten by frontline AML, and frontline is gated to KOMET-017 Phase 3 topline expected in 2028. So the leg an investor buys here is a launch-curve compounding story with an option on 2H 2026 combination datasets — not a dated re-rating event. Price agrees: $10.86 on 2026-08-14, still 10.5% under the post-approval high, RSI 58.3, no breakout.

Bullish and bearish views on Kura Oncology, Inc.

The model's bull view on Kura Oncology, Inc. (KURA), in brief: KOMZIFTI net product revenue $9.1M in Q2 2026, +57% QoQ off $5.8M in Q1 and a $2.1M Q4'25 launch stub (first sale 2025-11-21) — three quarters of sequential acceleration in the approved niche (Q2 release, 2026-08-12). The bear view: Top line missed: total revenue $20.874M versus $21.420M consensus (2026-08-12), with collaboration revenue $11.8M against $15.3M in Q2 2025 — the partnered line is lumpy and shrank year over year. Both cases follow in full.

Bull Case

• KOMZIFTI net product revenue $9.1M in Q2 2026, +57% QoQ off $5.8M in Q1 and a $2.1M Q4'25 launch stub (first sale 2025-11-21) — three quarters of sequential acceleration in the approved niche (Q2 release, 2026-08-12).
• Share of new patient starts moved from ~40% at the Q1/EHA 2026 update (2026-06-14) to a stated majority of new starts in the R/R NPM1-m menin class by Q2 — Kura is taking the class despite Syndax's Revuforj reaching market first.
• Bottom line beat: Q2 EPS $(0.77) versus $(0.87) consensus (2026-08-12), with R&D $61.9M and SG&A $31.8M against a $68.3M net loss.
• Frontline dataset supporting KOMET-017 remains strong: KOMET-007 long-term results (2026-06-12) showed 96% CR in NPM1-m and 90% in KMT2A-r, with 12-month overall survival of 94% and 71% respectively.
• No QTc-prolongation/Torsades boxed warning on ziftomenib, versus revumenib's — the differentiator that matters as the class moves into chemotherapy combinations.
• Balance sheet covers the wait: $519.0M cash and short-term investments at 2026-06-30 plus $180M of anticipated Kyowa Kirin payments, which the company says funds ziftomenib AML development through the 2028 KOMET-017 topline. Collaboration revenue guided to $45–55M in 2026 and $90–110M in each of 2027 and 2028.
• Sell-side sits far above the tape: Wedbush $38 (2026-08-13), Citizens $24 (2026-06-15); stockanalysis.com's aggregation of 10 analysts over the trailing three months shows an average $28.13 with a $15–40 range.

Bear Case

• Top line missed: total revenue $20.874M versus $21.420M consensus (2026-08-12), with collaboration revenue $11.8M against $15.3M in Q2 2025 — the partnered line is lumpy and shrank year over year.
• Cash and short-term investments fell to $519.0M at 2026-06-30 from $580.8M at 2026-03-31 while the quarterly net loss ran $68.3M; the stated runway to 2028 depends on $180M of Kyowa milestones arriving on schedule.
• The dated re-rating event is roughly two years out. Company-listed milestones run 2H 2026 (KOMET-007 quizartinib/7+3 initial data, KOMET-008 gilteritinib initial data, updated ven/aza long-term data, KOMET-001 MEIS1 exploratory analysis), 1H 2027 (FIT-001 Phase 1b enrollment complete), 2H 2027 (FIT-001 initial data), then 2028 KOMET-017 topline.
• The approved label is still a narrow R/R NPM1 monotherapy niche. Nine months post-approval the stock has not reclaimed its 2025-11-14 high, so the market is discounting frontline adoption that has not been demonstrated commercially.
• Class competition is not standing still: Syndax's revumenib covers both KMT2A-r and R/R NPM1, with J&J's bleximenib, Sumitomo's enzomenib and Servier's S243249 advancing.
• Between the 2026-08-12 print and roughly early-November, the calendar carries no company-confirmed event; the 2H 2026 datasets have no announced venue or date.

Setup & Price Structure

Reference close $10.86 (2026-08-14), 10.5% below the $12.14 52-week high, RSI(14) 58.3, three-month return +17.8%. That combination describes a recovered but unresolved base: the July drift into the low-$10s reversed into the print, and the 2026-08-13 session put KURA on Benzinga's list of large movers higher, yet the advance has not produced a new 52-week high. Momentum is mid-range, not extended — RSI in the 50s leaves no evidence of a stretched, crowded push.

Crowding and positioning observables, stated as observables: (1) the gap between Street targets and the tape is wide — $38 top-of-book against a $10.86 close, a $15 low estimate in the aggregated range — which is a divergence to watch resolve in either direction, not a valuation argument; (2) the earnings event is behind, not ahead, so there is no imminent print to compress the setup, with the next report estimated near early-to-mid November on the 2026-05-12 / 2026-08-12 cadence; (3) the recent filing feed for the name shows no Form 4 insider transactions and no offering into this strength — absence of evidence in a short feed, not a clean bill; (4) retail-sentiment coverage on the name has been episodic around print dates rather than continuous, which is the opposite of the clustering that marks a saturated retail bid.

The narrative is maturing. Dating it — the approval headline is nine months old (2025-11-13), the stock's high was set 2025-11-14 and has not been retaken, and the incremental buyer is now underwriting a commercial ramp ($5.8M → $9.1M, Q1 to Q2 2026) rather than a binary. The narrative still works and still produces target raises (2026-08-13), but attention is moderating and the flow is event-shaped. Confirmation of a shift back toward accelerating would be a weekly close above the $12.14 high on expanding volume alongside a third consecutive sequential product-revenue step.

Catalyst Calendar (next 30 days)

• No company-confirmed catalyst falls inside 2026-08-16 → 2026-09-15. The Q2 report cleared on 2026-08-12; the 2H 2026 data presentations have no announced date or venue as of 2026-08-14. This is a genuinely empty window, and treating any September date as scheduled would be invention.
• ~2026-11-10 (est.): Q3 2026 report, extrapolated from the 2026-05-12 (Q1) and 2026-08-12 (Q2) dates. The number that matters is KOMZIFTI product revenue against $9.1M and new patient starts against ~115.
• 2H 2026 (est., venue unconfirmed): initial KOMET-007 ziftomenib + quizartinib + 7+3 data and initial KOMET-008 gilteritinib-combination data, plus updated long-term ven/aza results.

Elapsed catalysts

• 2026-08-10 (elapsed, still circulating): publication in Blood detailing the discovery and preclinical development of ziftomenib — a credibility item, not a valuation event. (passed 16d ago)

What Would Change Our Mind

The structure that must hold is the three-month advance built into the Q2 print. Giving that back would say the launch inflection did not change how the market prices a company whose next transformational readout is two years out: a weekly close below $9.50 does exactly that, erasing the +17.8% three-month move and returning price to pre-advance levels. A secondary break, on fundamentals rather than tape: KOMZIFTI product revenue failing to grow sequentially from $9.1M at the estimated ~2026-11-10 Q3 report, or new patient starts printing below the ~115 recorded in Q2 — that ends the compounding-launch leg regardless of price. A third condition is calendar decay: if the 2H 2026 KOMET-007 quizartinib and KOMET-008 datasets pass without a presentation date being announced, the theme has effectively flipped to a pure 2028 wait. On the other side, a weekly close above $12.14 with a third sequential product-revenue step would argue the label should move from maturing to accelerating.

Correlation Notes

• Direct read-across to Syndax (SNDX): the two share the menin-inhibitor R/R NPM1 market, and Syndax's quarterly Revuforj disclosure is the cleanest external check on Kura's claimed majority share of new starts. Sequential Revuforj strength alongside decelerating KOMZIFTI starts would settle the share question against Kura.
• Partner exposure to Kyowa Kirin: ziftomenib carries a 50/50 US profit share under the November 2024 collaboration (up to $1.161B in total consideration), so US economics are shared and ex-US value accrues to the partner. The $180M of anticipated payments is also the pivot of the runway claim.
• Small/mid-cap biotech beta: with no dated binary until 2028 and a loss-making P&L ($68.3M net loss in Q2 2026), the name trades with the XBI/rate-sensitivity complex between prints more than on its own news.
• Frontline AML competitive complex: J&J (bleximenib), Sumitomo (enzomenib) and Servier (S243249) datasets are read-across risk to the KOMET-017 frontline thesis even though none of them changes Kura's current revenue line.